JP2020513014A5 - - Google Patents

Download PDF

Info

Publication number
JP2020513014A5
JP2020513014A5 JP2019554840A JP2019554840A JP2020513014A5 JP 2020513014 A5 JP2020513014 A5 JP 2020513014A5 JP 2019554840 A JP2019554840 A JP 2019554840A JP 2019554840 A JP2019554840 A JP 2019554840A JP 2020513014 A5 JP2020513014 A5 JP 2020513014A5
Authority
JP
Japan
Prior art keywords
composition according
composition
subject
compound
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019554840A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513014A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/026631 external-priority patent/WO2018187792A1/en
Publication of JP2020513014A publication Critical patent/JP2020513014A/ja
Publication of JP2020513014A5 publication Critical patent/JP2020513014A5/ja
Priority to JP2023009479A priority Critical patent/JP2023052629A/ja
Priority to JP2024224325A priority patent/JP2025041753A/ja
Pending legal-status Critical Current

Links

JP2019554840A 2017-04-07 2018-04-07 ２’−フコシルラクトース化合物による炎症性腸疾患の治療 Pending JP2020513014A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023009479A JP2023052629A (ja) 2017-04-07 2023-01-25 ２’－フコシルラクトース化合物による炎症性腸疾患の治療
JP2024224325A JP2025041753A (ja) 2017-04-07 2024-12-19 ２’－フコシルラクトース化合物による炎症性腸疾患の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482840P 2017-04-07 2017-04-07
US62/482,840 2017-04-07
PCT/US2018/026631 WO2018187792A1 (en) 2017-04-07 2018-04-07 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023009479A Division JP2023052629A (ja) 2017-04-07 2023-01-25 ２’－フコシルラクトース化合物による炎症性腸疾患の治療

Publications (2)

Publication Number Publication Date
JP2020513014A JP2020513014A (ja) 2020-04-30
JP2020513014A5 true JP2020513014A5 (https=) 2021-04-15

Family

ID=63712677

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019554840A Pending JP2020513014A (ja) 2017-04-07 2018-04-07 ２’−フコシルラクトース化合物による炎症性腸疾患の治療
JP2023009479A Pending JP2023052629A (ja) 2017-04-07 2023-01-25 ２’－フコシルラクトース化合物による炎症性腸疾患の治療
JP2024224325A Pending JP2025041753A (ja) 2017-04-07 2024-12-19 ２’－フコシルラクトース化合物による炎症性腸疾患の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023009479A Pending JP2023052629A (ja) 2017-04-07 2023-01-25 ２’－フコシルラクトース化合物による炎症性腸疾患の治療
JP2024224325A Pending JP2025041753A (ja) 2017-04-07 2024-12-19 ２’－フコシルラクトース化合物による炎症性腸疾患の治療

Country Status (8)

Country Link
US (2) US20200129534A1 (https=)
EP (1) EP3606535A4 (https=)
JP (3) JP2020513014A (https=)
CN (1) CN110730665A (https=)
AU (2) AU2018250337B2 (https=)
BR (1) BR112019020911A2 (https=)
CA (1) CA3059265A1 (https=)
WO (1) WO2018187792A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021111422A1 (en) * 2019-12-06 2021-06-10 Glycom A/S Composition comprising 2'-fl and dfl for use in a method for reducing pain
CN111698994A (zh) 2017-11-30 2020-09-22 格礼卡姆股份公司 治疗小麦敏感性的hmo混合物
BE1027078A9 (nl) 2019-02-25 2020-09-28 Nutribam Bvba Samenstelling, voedingssupplement en werkwijze voor het ondersteunen en/of verbeteren van de darmgezondheid
WO2020174386A1 (en) 2019-02-25 2020-09-03 Nutribam Bvba Composition, food supplement and method for supporting and/or improving intestinal health
EP4058031A4 (en) * 2019-11-14 2023-11-08 Glycom A/S SYNTHETIC COMPOSITION FOR BALANCING THE BALE ACID PROFILE IN THE INTESTINAL
CN111588726A (zh) * 2020-04-28 2020-08-28 南开大学 2′-岩藻糖基乳糖调节宿主肠道菌群及增强肠屏障的应用
CN116615203B (zh) * 2020-12-11 2025-03-07 帝斯曼知识产权资产管理有限公司 改进的益生元制剂
CN113486954B (zh) * 2021-07-06 2023-04-07 广西爱生生命科技有限公司 一种肠道微生态差异菌分类处理方法及肠道健康评估方法
WO2023102071A1 (en) * 2021-12-01 2023-06-08 Cedars-Sinai Medical Center Microbial metabolites on intestinal inflammation
US20250213600A1 (en) 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
CN119842563B (zh) * 2025-03-17 2025-06-06 昆明医科大学第一附属医院(云南省皮肤病医院) 多尔氏菌emf18-06b1d及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2451462B1 (en) * 2009-07-06 2017-09-06 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
WO2012009315A2 (en) * 2010-07-12 2012-01-19 The Regents Of The University Of California Bovine milk oligosaccharides
US20120020941A1 (en) * 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
JP6129821B2 (ja) * 2011-05-13 2017-05-17 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用
WO2013154725A1 (en) * 2012-04-13 2013-10-17 Trustees Of Boston College Prebiotic compositions and methods of use
EP2687845A1 (en) * 2012-07-20 2014-01-22 Nestec S.A. Fucose as a biomarker for gut immunity
PL3212198T3 (pl) * 2014-10-29 2021-08-23 Glycom A/S Syntetyczna kompozycja i sposób promowania gojenia się błony śluzowej
AU2016208455A1 (en) * 2015-01-23 2017-06-15 Société des Produits Nestlé S.A. Nutritional composition useful in the treatment of IBD patients
EP3862002A1 (en) * 2015-01-26 2021-08-11 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
US10751354B2 (en) * 2015-09-14 2020-08-25 Glycom A/S Synthetic composition for microbiota modulation

Similar Documents

Publication Publication Date Title
JP2020513014A5 (https=)
Marotto et al. Extra-intestinal manifestations of inflammatory bowel diseases
CA3059265A1 (en) Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds
Prantera et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease
Kerr et al. Early life events influence whole-of-life metabolic health via gut microflora and gut permeability
Ji et al. Lentinan improves intestinal inflammation and gut dysbiosis in antibiotics-induced mice
Lee et al. Henoch-Schonlein Purpura in children hospitalized at a tertiary hospital during 2004-2015 in Korea: epidemiology and clinical management
CN105682664A (zh) 利用岩藻糖基化低聚糖预防或治疗非分泌型母亲诞下或喂养的婴儿的变态反应的组合物，尤其适用于有风险的婴儿或剖腹产婴儿
EA021890B1 (ru) Способ предотвращения и/или лечения болезни воспаленного кишечника, язвенного колита и болезни крона
RU2008140167A (ru) Применение неусвояемых сахаридов для лучшей адаптации младенцев после рождения
JP2010526055A (ja) エキソ多糖
Kim et al. Ameliorating effect of 2′-fucosyllactose and 6′-sialyllactose on lipopolysaccharide-induced intestinal inflammation
CN112165947A (zh) 用于治疗自身免疫性疾病的hmo混合物
CN114886119B (zh) 3’-唾液酸乳糖在制备缓解食物过敏的功能性食品中的应用
Zimmermann et al. Consumption of yeast-fermented wheat and rye breads increases colitis and mortality in a mouse model of colitis
JP2016525138A (ja) 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
JP5358219B2 (ja) 腸疾患治療剤
Kim et al. Acute pancreatitis associated with indigo naturalis in pediatric severe Crohn’s disease
Rosyid et al. Effectiveness of Zinc Therapy with Zinc-Probiotic Combination Therapy on the Duration of Diarrhea During Hospitalization at Mawaddah Medika Hospital in October-December 2023
Gupta et al. Current approaches for treatment of colonic disorder
JP7519710B2 (ja) 腸内環境改善剤
CN1174773C (zh) 一种治疗消化道疾病的药物及其制备方法
Cleveland et al. 2075 tandem therapy using cyclosporine and tofacitinib for the treatment of severe ulcerative colitis
Yuan et al. Crohn’s disease
Kjeldsen-Kragh Dietary treatment of rheumatoid arthritis